Moloney Securities Asset Management’s Northwest Biotherapeutics, Inc. Common stock NWBO Stock Holding History

Moloney Securities Asset Management’s Portfolio NWBO Stock Details NWBO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	$128K	Buy	534,710 +33,150	+7%	+$7.96K	0.02%	460
2025 Q2	$120K	Buy	501,560 +1,440	+0.3%	+$345	0.01%	459
2025 Q1	$114K	Buy	500,120 +11,600	+2%	+$2.65K	0.02%	451
2024 Q4	$134K	Buy	488,520 +26,305	+6%	+$7.23K	0.02%	433
2024 Q3	$148K	Buy	462,215 +37,905	+9%	+$12.1K	0.02%	449
2024 Q2	$181K	Buy	424,310 +44,850	+12%	+$19.1K	0.03%	431
2024 Q1	$197K	Buy	379,460 +21,300	+6%	+$11.1K	0.03%	414
2023 Q4	$251K	Buy	358,160 +5,500	+2%	+$3.85K	0.04%	361
2023 Q3	$321K	Buy	352,660 +23,000	+7%	+$20.9K	0.06%	304
2023 Q2	$187K	Buy	329,660 +45,500	+16%	+$25.8K	0.03%	379
2023 Q1	$178K	Sell	284,160 -1,300	-0.5%	-$813	0.03%	383
2022 Q4	$224K	Buy	285,460 +300	+0.1%	+$235	0.05%	344
2022 Q3	$204K	Buy	285,160 +700	+0.2%	+$501	0.05%	336
2022 Q2	$179K	Buy	284,460 +5,995	+2%	+$3.77K	0.04%	340
2022 Q1	$194K	Buy	278,465 +46,400	+20%	+$32.3K	0.04%	381
2021 Q4	$162K	Buy	232,065 +63,800	+38%	+$44.5K	0.03%	416
2021 Q3	$215K	Buy	168,265 +8,600	+5%	+$11K	0.04%	383
2021 Q2	$235K	Buy	159,665 +20,720	+15%	+$30.5K	0.04%	367
2021 Q1	$207K	Buy	138,945 +34,895	+34%	+$52K	0.04%	372
2020 Q4	$159K	Buy	104,050 +54,650	+111%	+$83.5K	0.04%	360
2020 Q3	$38K	Buy	49,400 +17,400	+54%	+$13.4K	0.01%	323
2020 Q2	$11K	Buy	32,000 +1,000	+3%	+$344	﹤0.01%	304
2020 Q1	$5K	Buy	+31,000	New	+$5K	﹤0.01%	281

Other funds holding NWBO

VWA

VSM Wealth Advisory Hunt Valley, Maryland $376M AUM 21.56% 1-Year Est. Return

OCG

Opus Capital Group Cincinnati, Ohio $930M AUM 16.14% 1-Year Est. Return

WJWM

Williams Jones Wealth Management New York $8.14B AUM 19.32% 1-Year Est. Return

EFG

Ethos Financial Group King Of Prussia, Pennsylvania $1.37B AUM 19.43% 1-Year Est. Return

KLCM Advisors Milwaukee, Wisconsin $1.19B AUM 34.45% 1-Year Est. Return

AMG

Advisors Management Group La Crosse, Wisconsin $549M AUM 29.35% 1-Year Est. Return

Moloney Securities Asset Management's NWBO Position: Q3 2025 in Review

Moloney Securities Asset Management increased its Northwest Biotherapeutics, Inc. Common stock (NWBO) stake by 6.6% in Q3 2025, buying an estimated $7.96K and bringing the position to 534,710 shares worth $128K. The position accounts for 0.02% of the portfolio, ranked #460.

Moloney Securities Asset Management first reported a position in NWBO in Q1 2020 and has held it in 23 quarters since. The position peaked at $321K in Q3 2023. 9 funds tracked by Wall St. Rank hold NWBO as of Q3 2025.

Moloney Securities Asset Management held 534,710 shares of Northwest Biotherapeutics, Inc. Common stock worth $128K as of Q3 2025.
Moloney Securities Asset Management bought 33,150 Northwest Biotherapeutics, Inc. Common stock shares in Q3 2025, an estimated $7.96K.
Northwest Biotherapeutics, Inc. Common stock made up 0.02% of Moloney Securities Asset Management's portfolio in Q3 2025, its #460 holding.
Moloney Securities Asset Management first reported a position in Northwest Biotherapeutics, Inc. Common stock in Q1 2020 and has held it in 23 quarters since.
Moloney Securities Asset Management's Northwest Biotherapeutics, Inc. Common stock position peaked at $321K in Q3 2023.
9 funds tracked by Wall St. Rank held Northwest Biotherapeutics, Inc. Common stock as of Q3 2025.

Based on Moloney Securities Asset Management's 13F filing for Q3 2025, filed 5 Nov 2025.